Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Eisai signs licensing agreement with Nobelpharma
According to Eisai, Gliadel wafer is the only FDA-approved chemotherapeutic implant for use during surgical procedures for malignant glioma. Gliadel wafer has been approved in 18 countries worldwide,
According to Eisai, Gliadel wafer is the only FDA-approved chemotherapeutic implant for use during surgical procedures for malignant glioma. Gliadel wafer has been approved in 18 countries worldwide,
Insmed, a biopharmaceutical company, has successfully closed the sale of all of the company’s assets related to its follow-on biologics business to a subsidiary of Merck & Co.
The transaction is expected to close during the second quarter of 2009, subject to customary closing conditions. Piedmont Research Center (PRC) offers non-Good Laboratory Practice preclinical efficacy testing
The partnership combines Carroll Hospital Group’s new medical-surgical bed, Spirit Select, with Kinetic Concepts’s broad mattress replacement portfolio, which includes multiple products that are believed to provide superior
Sepracor, a research-based pharmaceutical company, has submitted a new drug application to the FDA for the use of eslicarbazepine acetate as adjunctive therapy in the treatment of partial-onset
Under the two-year agreement, Kingchem will act as an agent to find a US pharmaceutical company to co-develop Sinobiopharma’s Chinese patented new version of cisatracurim besylate, a non-depolarizing
According to PPD, the acquisition expands its compound partnering program into dermatology, initially in the indications of psoriasis, atopic dermatitis and acne. With the acquisition, PPD gains a
The company expects to earn gross proceeds of approximately $31 million, before deducting placement agent’s fees and estimated offering expenses. The investors have agreed to purchase the units
Taro’s carbamazepine extended-release tablets are bioequivalent to the reference listed drug Tegretol-XR tablets of Novartis Pharmaceuticals, a prescription pharmaceutical product used for treating seizures. The FDA has informed
Alexion Pharmaceuticals, a biopharmaceutical company, has submitted a new drug application for Soliris as a treatment for patients with paroxysmal nocturnal hemoglobinuria to Japan’s Pharmaceuticals and Medical Devices